Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Roshini Claire Anthony, 5 days ago

Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.

High-intensity focused ultrasound safe, effective in radiocurrent prostate cancer

22 Dec 2017

Treatment of radiocurrent prostate cancer with whole gland high-intensity focused ultrasound is reasonably safe and effective, according to a recent study.

“The rate of complications, which are potentially severe, was acceptable, especially considering the advanced, refractory nature of the disease and the limited treatment options,” researchers said.

A total of 100 men (mean age 70 years) were treated, of whom 78 completed the 12-month biopsy, which was negative in 63 (81 percent).

The median Gleason score was 7 and mean prostate-specific antigen was 4.9 ng/ml (range, 0.4‒14). Fifty men achieved the 1-year endpoint of a prostate-specific antigen nadir of ≤0.5 ng/ml and negative biopsy. Mean prostate-specific antigen at 2 years was 1.1 ng/ml (range, 0.1‒17) in 22 patients during post-trial follow-up.

Ninety-one men developed adverse events (AEs) through 12 months (grade 1 in 67; grade 2 in 80; and grade 3 in 20). Treatment-related grade 3 AEs included rectal fistulas (n=5; surgery required in 3), osteitis pubis (n=3), and haematuria (intervention required in 3). Treatment-related grade 3 AEs developed early in the trial and were potentially linked to operator experience.

No life-threatening AEs or treatment-related deaths were reported.

In this study, men (n=100) with clinically localized recurrent prostate cancer at least 2 years following external beam radiation therapy underwent whole gland high intensity focused ultrasound in an open-label trial from 2009 to 2012.

The combination of a prostate-specific antigen nadir of ≤0.5 ng/ml and negative biopsy at 12 months was the primary endpoint. Researchers administered validated questionnaires to monitor changes in urinary and sexual function.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Stephen Padilla, 12 Dec 2019
Transitioning from bortezomib- to ixazomib-based induction is feasible, tolerable and effective in the treatment of community patients with newly diagnosed multiple myeloma (NDMM), according to a study presented at the 61st Annual Meeting of the American Society of Hematology (ASH 2019).
Jackey Suen, 24 Feb 2017

Research on the role of circulating tumour DNA (ctDNA) in metastatic castration-resistant prostate cancer (mCRPC) gains momentum, as a new study finds ctDNA assessment promising in the monitoring and prognosis of mCRPC and in identifying new therapeutic targets for the disease.

13 Feb 2020
At the recent National Haematology Expert Meeting 2019, a panel of experts was convened to discuss the role of targeted therapy in the management of haematological malignancies. Highlights of their lectures are summarised below.
Roshini Claire Anthony, 5 days ago

Neoadjuvant chemotherapy with S-1 and oxaliplatin (SOX) may be a suitable treatment measure for patients with advanced gastric or esophagogastric junction adenocarcinoma, according to the RESONANCE* trial presented at ASCO GI 2020.